Illumina Inc
USUSDIllumina Inc (US:ILMN) — Medical Specialities. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- illumina.com
- Investor relations
- investor.illumina.com/investors/default.aspx
- Sector
- Health Care · Medical Specialities
- Headquarters
- San Diego, United States
- Management
- Employees
- 9 250
- Founded
- 1998
- IPO
- 2000-06-28
- Shares outstanding
- Free float
- 149.78 M
- Market cap
- 43.8 B USD
- Insiders
- 0.21%
- Institutions
- 106.47%
- Industry (SIC)
- Laboratory Analytical Instruments
- Legal form
- XTIQ
- ISIN
- US4523271090
- LEI
- SQ95QG8SR5Q56LSNF682
- P/EP/E (Price / Earnings) — how many years of the company's profit you pay for a share. Calculated: current price ÷ net earnings per share over the last 12 months. Lower means cheaper relative to profit. Not calculated when the company has a loss (—).
- 34.5
- EPSEPS (Earnings Per Share) — the company's net profit over the last 12 months divided by the number of its shares, in the currency of this listing. A negative value (red) means a loss. P/E is the share price divided by EPS.
- 5.81 USD
- |P/B (price to book) — share price ÷ shareholders' equity per share from the latest balance sheet. Graham — as Benjamin Graham counted it: equity without goodwill, other intangible assets and preferred stock, that is tangible book value. He considered up to 1.5 acceptable for a defensive investor (green), or a product P/E × P/B up to 22.5. With negative tangible equity, Graham's P/B is not calculated.
- 9.6520.6
- Graham numberGraham number — the highest price Benjamin Graham considered reasonable for a defensive investor: √(22.5 × EPS × tangible book value per share), where 22.5 = P/E 15 × P/B 1.5. A price below it (green) passes both of his limits at once. Not calculated with a loss or negative tangible equity.
- 35.65 USD price 463% above
- ROEROE (return on equity) is net income over the last 12 months divided by average shareholders' equity over those 12 months. It shows how much profit the company earns on every 100 dollars of capital. Consistently above 15% is a sign of a strong business, but a high ROE can also come from heavy debt or small equity after buybacks. One-off gains (sale of a business, revaluation, tax benefit) are excluded; «!» explains why the value differs from the reported one or is unreliable. Companies with negative equity have no ROE.
- 32.5%
- Payout ratioPayout ratio — what share of net income the company pays out as dividends. Calculated: dividends paid over the last 12 months ÷ net income for the same 12 months × 100%. Up to 60% — safe margin, 60–90% — borderline, over 90% — dividend at risk of a cut. «Loss» — the company pays without a profit.
- 0%
- FCFFCF (Free Cash Flow) — money left to the company after operating costs and investment in equipment; dividends are safest when paid from it. Calculated: operating cash flow − capital expenditure, over the last 12 months, in the reporting currency.
- 1.06 B USD
- DebtDebt — all loans and bonds of the company per the latest report (short- and long-term), in the reporting currency. Below — how many years the company would need to repay net debt (debt minus cash) from its free cash flow: net debt ÷ FCF. Up to 3 years — good, 3–6 — moderate, over 6 — high. «Net cash» — net debt is negative.
Debt 1.79 B USD FCF 1.06 B USD Total debt / FCF 1.7 y The years shown on the page use net debt: cash on hand can be used to repay debt at any time. - 1.79 B USD1.7 y of FCF
- Earnings, FCF and dividends paid — for the 12 months to 27.09.2026 (the company's latest report).
- Net income
- NAVNAV — net asset value by the balance sheet: the company's assets minus its liabilities, the share of the company's shareholders (without other owners' stakes in its subsidiaries). Shown per share, with P/NAV — how many times the share price exceeds NAV per share (below 1 — the share costs less than its net assets on the balance sheet). Click to see what NAV is made of and its history.
Description
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Candles
Each candle is one trading day. The thick part runs from the open price to the close price: green — the day closed higher than it opened, red — lower. The thin line runs from the lowest to the highest price of the day. Hover or tap a day to see all four prices.
Dividends
Orange dashed line «ex» — the ex-date: to receive the payment you must hold the shares before this day (shares bought on this day or later come without the dividend). On this day the price often drops by roughly the dividend amount. Blue dashed line «$» — the payment date. Future dates (up to 45 days) are shown on the right on a grey background.
P/E
The share price divided by the company earnings per share for the last 12 months (EPS). It shows how many years the company would need to earn its current profit to «pay back» the price: a lower P/E means the stock is cheaper relative to earnings. The line has its own scale on the left.
For some companies earnings come from their quarterly reports: on the day of a new report P/E jumps (a purple tick at the bottom of the chart), between reports it changes only with the price. For others P/E uses current earnings, so before the latest report it is approximate. If earnings are negative, P/E is not shown.
My position
Visible only to you and only if this stock is among your open portfolio positions (purchases in the same currency as the chart exchange). From each purchase date there is a dashed line at the purchase price, and between it and each day close price — an area: green if the position is in profit, red if at a loss. If you sold part, the remainder is shown: a sale writes off the earliest purchases first. The day tooltip shows how many shares were in the position and the gain or loss in money and %.
Payout yield
The blue dashed curve with its own % scale on the left: for each day — the last payment amount divided by that day close price. That is, what percentage of the share price one payment makes: the price rises — the percentage falls, and vice versa; when the company changes the payment, the curve moves to the new amount. The annual yield is roughly this percentage times the number of payments per year.
Above each «$» mark — the percentage of that payment relative to the price on the payment day (for future ones — relative to the last price, marked «≈»). Only payments in the chart exchange currency are counted.
Dividends
| Ex-date | Payment | Amount | % | Type | Ticker |
|---|---|---|---|---|---|
| 2024-06-25 | — | 3.1051 USD | 1.6/1.6 % | — | LSE:0J8Z |
News this week
Press releases from the company's investor website, updated daily. Links lead to the company's website. Headlines are in the original language, as on the company website.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| Blackrock Inc. | 12.71% | 19.19 M | 2026-06-30 |
| Capital World Investors | 10.22% | 15.43 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.39% | 6.63 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.36% | 6.59 M | 2026-06-30 |
| State Street Corporation | 4.31% | 6.51 M | 2026-06-30 |
| WCM Investment Managemen… | 4.11% | 6.21 M | 2026-06-30 |
| iShares Trust-iShares Co… | 3.51% | 5.3 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.02% | 4.56 M | 2026-06-30 |
| FMR, LLC | 3% | 4.52 M | 2026-06-30 |
| AQR Capital Management,… | 2.35% | 3.54 M | 2026-06-30 |
| Primecap Management Comp… | 2.33% | 3.51 M | 2026-06-30 |
| AMERICAN BALANCED FUND | 2.31% | 3.49 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.18% | 3.3 M | 2026-06-30 |
| Geode Capital Management… | 1.95% | 2.95 M | 2026-06-30 |
| Growth Fund of America | 1.82% | 2.74 M | 2026-06-30 |
| New Economy Fund | 1.78% | 2.68 M | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 1.17% | 1.76 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 1.74 M | 2026-06-30 |
| WASHINGTON MUTUAL INVEST… | 1.04% | 1.57 M | 2026-07-31 |
| NEW PERSPECTIVE FUND | 0.93% | 1.4 M | 2026-06-30 |
| THAYSEN JACOB (Chief Exe… | ≈0.07% | 109 073 | 2026-03-05 |
| CUNNINGHAM EVERETT V (Of… | ≈0.03% | 50 840 | 2025-03-05 |
| BARNARD STEVEN (Chief Te… | ≈0.03% | 41 335 | 2026-03-05 |
| DHINGRA ANKUR (Chief Fin… | ≈0.02% | 34 264 | 2026-03-05 |
| PEGELS KEVIN CARL (Offic… | ≈0.02% | 29 038 | 2026-03-05 |
| SCHILLER PHILIP W (Direc… | ≈0.01% | 22 220 | 2026-05-21 |
| EPSTEIN ROBERT S (Direct… | ≈0.01% | 22 139 | 2025-05-21 |
| LECKMAN PATRICIA L (Offi… | ≈0.01% | 21 259 | 2026-06-05 |
| ARNOLD FRANCES H PH.D. (… | ≈0.01% | 20 907 | 2025-05-21 |
| MEISTER KEITH A (Directo… | — | — | 2026-09-04 |
